We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Malaria Tests Assessed After Artemisinin Therapy

By LabMedica International staff writers
Posted on 21 Oct 2013
Plasmodium falciparum-specific rapid diagnostic tests (RDTs) have been used to detect recurrent infections after artemisinin-based combination therapy (ACT).

High specificity of RDTs to distinguish an active P. More...
falciparum infection from residual antigens from a previous infection is crucial in endemic areas where residents are repeatedly exposed to malaria.

Scientists at Karolinska Institute (Stockholm, Sweden) studied 53 Tanzanian children less than five years of age with uncomplicated P. falciparum malaria infections. The children were followed up on nine occasions after initiation of artemether-lumefantrine treatment. At each visit capillary blood samples was collected for the histidine-rich protein 2 (HRP2 and lactate dehydrogenase (LDH)-based RDTs, Giemsa and acridine orange-stained blood smears for microscopy and real-time polymerase chain reaction (PCR).

The two RDTs used were the ParaHITf (Span Diagnostics Ltd.; Surat, India) that detects P. falciparum-specific HRP2 antigen and the CareStart Malaria assay (AccessBio; Somerset, NJ, USA) that detects P. falciparum-specific LDH antigen and were performed and interpreted on site. PCR genotyping was performed to distinguish reinfections from recrudescence. Assessment of clearance times and detection of recurrent P. falciparum infections were done for all diagnostic methods.

The median clearance times were 28 (range 7 to greater than 42) and 7 (2 to 14) days for HRP2 and LDH-based RDTs, 2 (1 to 7) and 2 (1 to 14) days for Giemsa and acridine orange-stained blood smear and 2 (1 to 28) days for real-time PCR. RDT specificity against Giemsa-stained blood smear microscopy was 21% for HRP2 on day 14, reaching 87% on day 42, and equal to or greater than 96% from day 14 to 42 for LDH. There was no significant correlation between parasite density at enrolment and duration of HRP2 positivity. Recurrent malaria infections occurred in 10 children and the HRP2 did not detect eight recurrent infections and LDH-based RDTs did not detect two.

The authors concluded that the LDH-based RDT was superior to HRP2-based for monitoring of treatment outcome and detection of recurrent infections after ACT in this moderately high transmission setting. The results may have implications for the choice of RDT devices in similar transmission settings for improved malaria case management. The study was published on October 1, 2013, in the Malaria Journal.

Related Links:
Karolinska Institute
Span Diagnostics Ltd.
Access Bio Inc.



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Researchers found that tumor DNA fragments in blood can reveal ongoing prostate cancer growth even when current tests show little change (image credit: Adobe Stock)

Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.